CSL830

PreclinicalBiologic

CSL Behring

CSL830 is one of 30 biologic programs targeting Hereditary Angioedema. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hereditary AngioedemaActive, not recruiting

Hereditary AngioedemaPreclinical

Active, not recruiting

Competition

Competitive Landscape

43 competitors in Hereditary Angioedema

#DrugCompanyPhaseTrials

Neoral

Crestor

Firazyr

5 4

Lanoxin

Andembry

1 6

Cyklokapron

AAmring

Phase 3

1 7

KALBITOR

Takeda

Phase 3

5 8

C1 Esterase Inhibitor

Takeda

Phase 3

8 9

Dawnzera (autoinjector)

Ionis Pharmaceuticals

Phase 3

6 10

Ruconest

PPharming Technologies B.V.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hereditary Angioedema1 trial

Expanded Access for Hereditary Angioedema (HAE)

Approved for marketing·JJoshua S. Jacobs, MD··NCT03177005

Tics1 trial

A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor

Completed· CSL Behring logo

CSL Behring·Phase 1·NCT01760343·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CSL830. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CSL830 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CSL830. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSL Behring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: CSL Behring

CSL830

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hereditary Angioedema1 trial

Tics1 trial

References

Drug Info

Quick Facts

Related News